Lee Harnatkiewicz serves as the Director of Financial Reporting at Onconova Therapeutics, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company. With over 20 years of extensive financial management experience, Lee has honed a robust expertise in SEC and GAAP reporting, particularly through his previous roles at newly-public...
Lee Harnatkiewicz serves as the Director of Financial Reporting at Onconova Therapeutics, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company. With over 20 years of extensive financial management experience, Lee has honed a robust expertise in SEC and GAAP reporting, particularly through his previous roles at newly-public companies and a Fortune 500 firm. His strategic involvement in the company’s successful IPO, including the meticulous preparation and filing of the S-1 registration statement, underscores his proficiency in navigating complex financial landscapes.
At Onconova, Lee plays a pivotal role in ensuring compliance with SEC regulations, overseeing all aspects of financial reporting, and maintaining rigorous internal controls in alignment with Sarbanes-Oxley requirements. His adeptness in financial modeling and managerial finance allows him to provide insightful analyses that drive informed decision-making within the organization. Lee’s collaborative approach is evident in his work with transfer agents and investment bankers, where he coordinates the IPO closing process and manages the direct share program, ensuring a seamless issuance of shares.
In addition to his technical skills, Lee is recognized for his strategic vision in mergers and acquisitions, leveraging his financial acumen to identify opportunities that align with Onconova’s growth objectives. His commitment to excellence in financial reporting not only enhances transparency for stakeholders but also supports the company’s mission to advance innovative therapies for cancer treatment. As a seasoned professional in the biopharmaceutical sector, Lee Harnatkiewicz continues to contribute significantly to Onconova’s financial integrity and operational success.
